Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

Core Insights - Glucotrack, Inc. is advancing its continuous blood glucose monitoring (CBGM) technology and plans to submit an Investigational Device Exemption (IDE) to the FDA in Spring 2026 [1][3] - The company has strengthened its balance sheet and expanded its clinical advisory team, appointing Dr. Usman Latif as a key expert in pain management and medical technology [1][5] Financial Highlights - For Q3 2025, research and development expenses increased to $3.2 million from $2.1 million in Q3 2024, primarily due to higher product and manufacturing development costs [7] - The net loss for Q3 2025 was $4.2 million, or $4.64 per share, compared to a net loss of $5.1 million, or $1,092 per share, in Q3 2024 [9] - For the nine months ended September 30, 2025, the company reported a net loss of $15.8 million, or $30.09 per share, compared to a net loss of $12.5 million, or $2,868 per share, for the same period in 2024 [12] Cash Position - As of September 30, 2025, cash and cash equivalents were $7.9 million, up from $5.6 million at the end of 2024, with a net increase attributed to $13.7 million in financing activities [13] Corporate Developments - The company has initiated a long-term multicenter feasibility study in Australia to evaluate the CBGM product's performance and safety [10] - Glucotrack presented at industry conferences, highlighting strong interest from endocrinologists in the CBGM product, with 73% of surveyed endocrinologists willing to prescribe it [10] - The company is committed to expanding its advisory boards with experts in endocrinology and cardiology to enhance its diabetes management solutions [10]